CG Oncology, Inc. (NASDAQ:CGON) Director Sells $29,660.00 in Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Leonard E. Post also recently made the following trade(s):

• On Friday, December 6th, Leonard E. Post sold 1,000 shares of CG Oncology stock. The shares were sold at an average price of $34.54, for a total value of $34,540.00.

CG Oncology Trading Down 1.7 %

Shares of NASDAQ CGON opened at $29.10 on Friday. The company’s 50-day simple moving average is $31.72 and its 200-day simple moving average is $34.16. CG Oncology, Inc. has a 52-week low of $25.77 and a 52-week high of $50.23.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.30 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. Equities analysts expect that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CGON has been the subject of several recent research reports. UBS Group initiated coverage on CG Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $60.00 price target for the company. TD Cowen initiated coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Bank of America restated a “buy” rating and set a $65.00 price target on shares of CG Oncology in a research report on Tuesday, October 8th. Royal Bank of Canada reiterated an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a research report on Friday, December 6th. Finally, HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of CG Oncology in a research note on Friday, January 10th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $63.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank grew its holdings in shares of CG Oncology by 107.6% during the third quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock worth $61,000 after buying an additional 840 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CG Oncology during the 3rd quarter valued at about $241,000. Profund Advisors LLC acquired a new stake in CG Oncology in the 2nd quarter valued at about $300,000. HighVista Strategies LLC purchased a new position in CG Oncology in the 3rd quarter worth approximately $594,000. Finally, M&T Bank Corp boosted its holdings in shares of CG Oncology by 55.7% during the 3rd quarter. M&T Bank Corp now owns 16,758 shares of the company’s stock worth $632,000 after purchasing an additional 5,996 shares during the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.